Hubei Jumpcan Pharmaceutical (600566.SH) subsidiary obtains drug registration certificate.

15:44 09/08/2026

Jichuan Pharmaceutical (600566.SH) announced that recently, its wholly-owned subsidiary Jichuan Pharmaceutical Group Co., Ltd. (referred to as "Jichuan Limited") received the drug registration certificates for Pediatric Laxative Granules and Mesalazine Sustained-Release Granules approved and issued by the National Medical Products Administration.

Hubei Jumpcan Pharmaceutical (600566.SH) announced that its wholly-owned subsidiary Hubei Jumpcan Pharmaceutical Group Co., Ltd. (referred to as "Jumpcan Limited") has recently received the Drug Registration Certificates for Pediatric Constipation Granules and Mesalazine Sustained-Release Granules approved by the National Medical Products Administration. The acquisition of the Drug Registration Certificates for Pediatric Constipation Granules and Mesalazine Sustained-Release Granules represents a further complement to the company's products, enriching its product line, and is expected to play a positive role in the company's future development.

Sealand: Air passenger transport is expected to stabilize and recover, and industry profitability may welcome improvement.

HK Stock Market Move | GENFLEET-B (02595) rose nearly 4% as GFH375 entered a Phase III clinical trial for the registration of monotherapy for non-small cell lung cancer in China.

HK Stock Market Move | WESTCHINACEMENT (02233) rose more than 10% during the session, expecting a net profit of up to 412 million yuan in the first half of the year, with overseas earnings growing against the trend.

Sealand: Air passenger transport is expected to stabilize and recover, and industry profitability may welcome improvement.

HK Stock Market Move | GENFLEET-B (02595) rose nearly 4% as GFH375 entered a Phase III clinical trial for the registration of monotherapy for non-small cell lung cancer in China.